COYA - Bathi operasional EBITDA Coya Therapeutics

Coya Therapeutics, Inc. (COYA) is entirely dependent on FDA verdicts regarding T-cell therapies, as it currently has no sales. On GURU.Markets, this operating financial result shows that the metric has reached the level of 0.00. The lack of profit is attributed to the outsourcing of trials to maintain flexibility and the use of third-party CDMO partners to scale biologics from Texas laboratories.

The implementation of robotic screening systems and AI modules for neurodrug analysis directly impacts the operational efficiency of Coya Therapeutics (COYA). The company's EBITDA trend reflects the net cash flow from core operations before taxes and interest, allowing investors to assess the business's actual ability to generate liquidity and the issuer's fundamental stability through a smoothed yield curve.